AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19733449 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study 22978725 — intervention group
Group type: EXPERIMENTAL
Intervention: REA‐ICU index
Number of subjects: 850
Study 22978725 — intervention group
Group type: COMPARATOR
Intervention: Pneumonia severity assessment tools (PSI and CURB‐65)
Number of subjects: 850
Study 22978725 — intervention group
Group type: COMPARATOR
Intervention: Alternate clinical prediction models (SMART‐COP, CURXO‐80, and the 2007 IDSA/ATS minor severity criteria)
Number of subjects: 850
Study 16187232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (aPBSC transplant with IL-2 incubation for 24 hours followed by parenteral IL-2 for 5 days, then 2 days of rest for 4 weeks)
Number of subjects: 59
Study 16187232 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy (aPBSC transplant without immunotherapy)
Number of subjects: 59
Study 16187232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 59
Study 16187232 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 59
Study 16187232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients developing acute graft versus host disease (aGVHD)
Number of subjects: 59
Study 12598277 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (150 microg) + incision site bupivacaine
Number of subjects: 120
Study 12598277 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 120
Study 12598277 — intervention group
Group type: COMPARATOR
Intervention: Epidural placebo + incision site bupivacaine
Number of subjects: 120
Study 12598277 — intervention group
Group type: COMPARATOR
Intervention: Placebo + incision site saline
Number of subjects: 120
Study 10100332 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% spacing condition with single-trial KR
Number of subjects: 10
Study 10100332 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% spacing condition with single-trial KR
Number of subjects: 10
Study 10100332 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% spacing condition with summary KR
Number of subjects: 10
Study 10100332 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% spacing condition with average KR
Number of subjects: 10
Study 10100332 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% spacing condition with summary KR
Number of subjects: 10
Study 10100332 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% spacing condition with average KR
Number of subjects: 10
Study 8652333 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg on the evening before and 40 mg on the morning of surgery
Number of subjects: 222
Study 8652333 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg on the evening before surgery and 2 h before anaesthesia
Number of subjects: 222
Study 8652333 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg on the morning of surgery
Number of subjects: 222
Study 1853694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (5 mg/kg)
Number of subjects: 106
Study 1853694 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 106
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder with expert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder with nonexpert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminder with expert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminder with nonexpert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct person‐to‐person reminder with expert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct person‐to‐person reminder with nonexpert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐home card reminder with expert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐home card reminder with nonexpert authority
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal commitment with enhanced importance message
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal commitment with standard importance message
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal plus written commitment with enhanced importance message
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal plus written commitment with standard importance message
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: No commitment with enhanced importance message
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: No commitment with standard importance message
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐home card reminder
Number of subjects: 0
Study 6879233 — intervention group
Group type: EXPERIMENTAL
Intervention: No reminder card
Number of subjects: 0
Study 28982956 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) followed by medical therapy
Number of subjects: 718
Study 28982956 — intervention group
Group type: COMPARATOR
Intervention: Topical medication without laser
Number of subjects: 718
Study 27832040 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 72
Study 27832040 — intervention group
Group type: COMPARATOR
Intervention: diet and exercise
Number of subjects: 72
Study 26271155 — intervention group
Group type: EXPERIMENTAL
Intervention: GC + bevacizumab
Number of subjects: 353
Study 26271155 — intervention group
Group type: COMPARATOR
Intervention: GC + PL
Number of subjects: 353
Study 23359390 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute stents
Number of subjects: 382
Study 23359390 — intervention group
Group type: COMPARATOR
Intervention: Xience V stents
Number of subjects: 382
Study 20538115 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PPCI) in real-world patients
Number of subjects: 1320
Study 20538115 — intervention group
Group type: COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PPCI) in DANAMI-2 trial patients
Number of subjects: 1320
Study 20538115 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted hazard ratio for real-world patients vs. DANAMI-2 patients after 1 year
Number of subjects: 1320
Study 20538115 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted hazard ratio for real-world patients vs. DANAMI-2 patients after 2 years
Number of subjects: 1320
Study 18181978 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily for 42 days
Number of subjects: 137
Study 18181978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 16611492 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective recall of ADHD symptoms
Number of subjects: 0
Study 16611492 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult reports of lifetime ADHD symptoms
Number of subjects: 0
Study 12791570 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of the NMDA receptor antagonist memantine
Number of subjects: 48
Study 12791570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10818175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetralogy of Fallot patients
Number of subjects: 41
Study 10818175 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 aged-matched asymptomatic subjects)
Number of subjects: 41
Study 10818175 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 8683961 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in heavy social drinkers (HSDs)
Number of subjects: 28
Study 8683961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam in heavy social drinkers (HSDs)
Number of subjects: 28
Study 8683961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam in light social drinkers (LSDs)
Number of subjects: 28
Study 8683961 — intervention group
Group type: COMPARATOR
Intervention: Placebo in light social drinkers (LSDs)
Number of subjects: 28
Study 1641288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge package containing a manual breast pump
Number of subjects: 146
Study 1641288 — intervention group
Group type: COMPARATOR
Intervention: Commercially available infant formula package
Number of subjects: 146
Study 6347380 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin, 2 mg/kg every eight hours for a minimum of 72 hours
Number of subjects: 30
Study 6347380 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin, 1 mg/kg every eight hours for a minimum of 72 hours
Number of subjects: 30
Study 29522138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib (400 mg once daily)
Number of subjects: 311
Study 29522138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib (200 mg twice daily)
Number of subjects: 311
Study 29522138 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 311
Study 26858332 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with esomeprazole and cola
Number of subjects: 28
Study 26858332 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib without esomeprazole and cola
Number of subjects: 28
Study 23799773 — intervention group
Group type: EXPERIMENTAL
Intervention: CISD
Number of subjects: 67
Study 23799773 — intervention group
Group type: COMPARATOR
Intervention: Screening
Number of subjects: 67
Study 23799773 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 67
Study 22816213 — intervention group
Group type: EXPERIMENTAL
Intervention: L2-3 spinal anesthesia with 15 mg 0.5% isobaric bupivacaine
Number of subjects: 72
Study 22816213 — intervention group
Group type: COMPARATOR
Intervention: L3-4 spinal anesthesia with 15 mg 0.5% isobaric bupivacaine
Number of subjects: 72
Study 22816213 — intervention group
Group type: EXPERIMENTAL
Intervention: L2-3 spinal anesthesia
Number of subjects: 72
Study 22816213 — intervention group
Group type: COMPARATOR
Intervention: L3-4 spinal anesthesia
Number of subjects: 72
Study 20405785 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG amplitude versus dynamic torque relationships for vastus lateralis (VL)
Number of subjects: 20
Study 20405785 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG amplitude versus dynamic torque relationships for rectus femoris (RF)
Number of subjects: 20
Study 20405785 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG amplitude versus dynamic torque relationships for vastus medialis (VM)
Number of subjects: 20
Study 20405785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficients for EMG amplitude versus torque coefficients
Number of subjects: 20
Study 18753098 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict bed rest
Number of subjects: 10
Study 18753098 — intervention group
Group type: COMPARATOR
Intervention: Normal activity
Number of subjects: 10
Study 15886747 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative bone scan of the sacroiliac joints (lambda parameter)
Number of subjects: 133
Study 12381637 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day amiloride (one month)
Number of subjects: 10
Study 12381637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10507091 — intervention group
Group type: EXPERIMENTAL
Intervention: Special pillow (Curavario, Pala-Medic-Company)
Number of subjects: 149
Study 10507091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative treatment (physical therapy including gymnastics, electrotherapy, thermotherapy, and massage)
Number of subjects: 149
Study 10507091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special pillow)
Number of subjects: 149
Study 7760967 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 therapy (75-100 micrograms T3 daily)
Number of subjects: 14
Study 7760967 — intervention group
Group type: COMPARATOR
Intervention: Hypothyroid phase
Number of subjects: 14
Study 7760967 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid control subjects
Number of subjects: 14
Study 2180493 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.1 mg/kg/d)
Number of subjects: 291
Study 2180493 — intervention group
Group type: COMPARATOR
Intervention: COP regimen (vincristine, cyclophosphamide, and prednisone)
Number of subjects: 291
Study 2180493 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 291
Study 2180493 — intervention group
Group type: COMPARATOR
Intervention: COP
Number of subjects: 291
Study 7005121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 0
Study 7005121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30776324 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (n=21)
Number of subjects: 50
Study 30776324 — intervention group
Group type: COMPARATOR
Intervention: NDSP (n=19)
Number of subjects: 50
Study 31648460 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCEL2 stent
Number of subjects: 419
Study 28711643 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom availability at work
Number of subjects: 946
Study 28711643 — intervention group
Group type: EXPERIMENTAL
Intervention: Incarceration
Number of subjects: 946
Study 25325454 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β estradiol 0.5 mg/day
Number of subjects: 339
Study 25325454 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR 75 mg/day
Number of subjects: 339
Study 25325454 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 339
Study 23271384 — intervention group
Group type: EXPERIMENTAL
Intervention: GLT < 90 mg/dL
Number of subjects: 436
Study 23271384 — intervention group
Group type: COMPARATOR
Intervention: GLT 90 to 119 mg/dL
Number of subjects: 436
Study 21542914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip school (group A) - 6 weeks, 5 sessions taught by a physiotherapist
Number of subjects: 0
Study 21542914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip school + Manual therapy (group B) - 6 weeks, 5 sessions of hip school + manual therapy twice a week
Number of subjects: 0
Study 21542914 — intervention group
Group type: COMPARATOR
Intervention: Minimal control intervention (group C) - self-care information leaflet with advice on 'live as usual' and stretching exercises from the hip school
Number of subjects: 0
Study 21542914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip school (group A)
Number of subjects: 0
Study 21542914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip school + Manual therapy (group B)
Number of subjects: 0
Study 21542914 — intervention group
Group type: COMPARATOR
Intervention: Minimal control intervention (group C)
Number of subjects: 0
Study 19070834 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) over DLPFC
Number of subjects: 24
Study 19070834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) over DLPFC
Number of subjects: 24
Study 19070834 — intervention group
Group type: COMPARATOR
Intervention: Sham theta burst stimulation (shamTBS)
Number of subjects: 24
Study 17562955 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 125
Study 17562955 — intervention group
Group type: EXPERIMENTAL
Intervention: 162 mg aspirin
Number of subjects: 125
Study 17562955 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 125
Study 17562955 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of aspirin
Number of subjects: 125
Study 15380908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric diet (130-150% of the caloric recommendation for age and sex) for 8 weeks
Number of subjects: 30
Study 15380908 — intervention group
Group type: COMPARATOR
Intervention: Normal caloric requirement for 8 weeks
Number of subjects: 30
Study 11475709 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips/Jordan electric toothbrush with Controlled Pressure system (CPS)
Number of subjects: 63
Study 11475709 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips/Jordan electric toothbrush with CPS set at various levels (150-420 g)
Number of subjects: 63
Study 9789533 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Fresh Frozen Plasma (FFP)
Number of subjects: 28
Study 9789533 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/Detergent Treated Pooled Fresh Frozen Plasma (SDFFP)
Number of subjects: 28
Study 9789533 — intervention group
Group type: COMPARATOR
Intervention: Control group (FFP)
Number of subjects: 28
Study 9789533 — intervention group
Group type: EXPERIMENTAL
Intervention: SDFFP
Number of subjects: 28
Study 8560161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunotherapy with Dermatophagoides extract
Number of subjects: 20
Study 8560161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2196627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) up to 300 mg daily for up to 10 weeks
Number of subjects: 519
Study 2196627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 362991 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate aerosol (BDA)
Number of subjects: 27
Study 362991 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 30798451 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Lyric Analysis (ELA)
Number of subjects: 69
Study 30798451 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Songwriting (ESW)
Number of subjects: 69
Study 30798451 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study 28220020 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM + CAP (10 mg/kg IV, days 1 and 8; 1,000 mg/m2 orally twice daily, days 1-14)
Number of subjects: 153
Study 28220020 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR + CAP (12 mg/kg IV, days 1 and 8; 1,000 mg/m2 orally twice daily, days 1-14)
Number of subjects: 153
Study 28220020 — intervention group
Group type: COMPARATOR
Intervention: CAP (1,000 mg/m2 orally twice daily, days 1-14)
Number of subjects: 153
Study 25267266 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insole
Number of subjects: 80
Study 25267266 — intervention group
Group type: COMPARATOR
Intervention: Valgus brace
Number of subjects: 80
Study 24099494 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis threat group
Number of subjects: 49
Study 24099494 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 21692289 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle retaining group
Number of subjects: 26
Study 21692289 — intervention group
Group type: COMPARATOR
Intervention: Quick needling group
Number of subjects: 26
Study 19700033 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt-based formula (diet 1)
Number of subjects: 154
Study 19700033 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (diet 4)
Number of subjects: 154
Study 19700033 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formula (diet 2)
Number of subjects: 154
Study 19700033 — intervention group
Group type: COMPARATOR
Intervention: Casein-based formula (diet 3)
Number of subjects: 154
Study 17122169 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush
Number of subjects: 101
Study 17122169 — intervention group
Group type: COMPARATOR
Intervention: Old toothbrush
Number of subjects: 101
Study 12970273 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, three times daily)
Number of subjects: 52
Study 12970273 — intervention group
Group type: COMPARATOR
Intervention: Dianette (ethinyl estradiol, 35 micro g; cyproterone acetate, 2 mg)
Number of subjects: 52
Study 10562262 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation patients
Number of subjects: 12084
Study 10562262 — intervention group
Group type: COMPARATOR
Intervention: Non-ST-segment elevation patients
Number of subjects: 12084
Study 8909666 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 receptor blocker (terfenadine 60 mg)
Number of subjects: 40
Study 8909666 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor blocker (ranitidine 300 mg)
Number of subjects: 40
Study 8909666 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 and H2 receptor blockers (terfenadine 60 mg and ranitidine 300 mg)
Number of subjects: 40
Study 8909666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no histamine receptor blocker)
Number of subjects: 40
Study 2072144 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus IFN alfa‐2b
Number of subjects: 64
Study 2072144 — intervention group
Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 64
Study 6222473 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin given during induction of anesthesia
Number of subjects: 0
Study 6222473 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3990155 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone treatment
Number of subjects: 52
Study 3990155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenobarbitone)
Number of subjects: 52
Study 28404766 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, sexual partner selection and risk decision intervention
Number of subjects: 0
Study 28404766 — intervention group
Group type: COMPARATOR
Intervention: Single-session, Centers for Disease Control and Prevention-based, sexual risk reduction intervention
Number of subjects: 0
Study 27381895 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prostate radiation (68.4Gy)
Number of subjects: 475
Study 27381895 — intervention group
Group type: COMPARATOR
Intervention: Postprostatectomy radiation (64.8Gy)
Number of subjects: 475
Study 24405796 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine intracervical injection
Number of subjects: 74
Study 24405796 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 2% lidocaine gel
Number of subjects: 74
Study 22863639 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical olive oil (1 cc, twice a day)
Number of subjects: 100